Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pidotimod and bifidobacteria in preschool children with recurrent respiratory infections
2015-002733-22Phase 3Completed
- Sponsor
- Valeas
- Start
- Apr 2018
- Modality
- Small Molecules, Peptides, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of pidotimod and Bifidobacteria in There is no canonical full disease name for "recurrent respiratory infections" because it is not recognized as a standalone disease entity in medical classification systems and Airways Infection, sponsored by Valeas. Primary endpoint: Number of respiratory infections. Started Apr 2018; status: completed.
02
Drugs
pidotimodBifidobacteria
03
Conditions
There is no canonical full disease name for "recurrent respiratory infections" because it is not recognized as a standalone disease entity in medical classification systems.Airways Infection
Beyond the preview
Go deeper on 2015-002733-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002733-22.